An artificial intelligence model that is being trained on de-identified data from 57 million people in England has the potential to predict future health risks and help improve healthcare ...

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US biotech Owkin.